Andere talen Kymera Therapeutics, Inc.

Aandelen

KYMR

US5015751044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 13-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
34,87 ^USD	+0,78%		+6,08%	+36,96%

11/06	Transcript : Kymera Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
01/06	Kymera Therapeutics presenteert nieuwe klinische gegevens van de lopende Fase 1-studie met MDM2-afbreker KT-253 op de jaarlijkse ASCO-bijeenkomst	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kymera Therapeutics : Corporate Presentation, June 2024	01/06
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	01/06
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	01/06
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	01/06
Kymera Therapeutics to Participate in Upcoming June Investor Conferences	29/05
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	23/05
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	23/05
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting	22/05
Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting	22/05
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting	14/05
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting	14/05
Kymera Therapeutics to Participate in Upcoming May Investor Conferences	08/05
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises	02/05
Kymera Therapeutics : Corporate Presentation, May 2024	02/05
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update	02/05
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders	02/05
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2	25/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kymera Therapeutics, Inc.

Aandelen

KYMR

US5015751044

Andere talen

Filters